Research advances in acute-on-chronic liver failure (ACLF) with reactivation of hepatitis B virus
10.3760/cma.j.issn.1003-9279.2019.01.024
- VernacularTitle: 乙型肝炎病毒再激活致慢加急性肝衰竭研究进展
- Author:
Huimin LIU
1
;
Qing MAO
Author Information
1. Department of Infectious Diseases, Southwest Hospital, Army Medical University (Third Military Medical University), The Chongqing Key Laboratory for Research of Infectious Diseases, Chongqing 400038, China
- Publication Type:Review
- Keywords:
Hepatitis B virus;
Reactivation;
Acute-on-chronic liver failure
- From:
Chinese Journal of Experimental and Clinical Virology
2019;33(1):108-113
- CountryChina
- Language:Chinese
-
Abstract:
The acute-on-chronic liver failure (ACLF) with reactivation of hepatitis B virus (HBV) leads to the difficulty in the treatment and the high mortality rate, but the incidence of HBV reactivation is increasing year by year. There are some high risk factors for the reactivation of HBV, such as the use of rituxan, the glucocorticoid, the chemotherapy, the direct-acting antiviral drugs against hepatitis C virus (HCV) and stopping the nucleot(s)ides analogues against HBV by oneself. The diagnostic criteria, risk factors, risk assessment of ACLF, prevention and management of HBV reactivation are reviewed in this article.
